Company News

2022-08-06
ImmuneOnco won "Drug Innovation Award" by Securities Times
On August 6, 2022, the Securities Times Biomedical Innovation Forum and the 2nd Drug Innovation Award Ceremony hosted by the Securities Times were held in Shanghai. Chairman founder of ImmuneOnco,Dr.Tian, Wenzhi,, was successfully selected as the "Top Ten Drug Innovation Scientists in 2021", and Drug candidate IMM2902 for Injection won the "Annual Drug Innovation Pioneering Award".
View more
2022-06-29
ImmuneOnco started Phase Ib/II Clinical Study of IMM01: An IMM01 combined with azacitidine clinical trial completed the first patient enrollment and dosing
On June 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that SIRPaFc recombinant protein targeting human CD47 ,IMM01, combined with azacitidine (AZA) in the treatment of relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) Phase Ib/II clinical study (clinical research project number: IMM01-02), completed the first patient enrollment for first dosing.
View more
2022-06-20
Phase I clinical trial of IMM2902 completed the first patient enrollment and dosing in the United States.
On June 20, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco" and the company) announced that, on June 20, local time, an FDA-registered Phase I clinical trial of the first globally novel bi-specific antibody-receptor fusion protein targeting human CD47xHER2(IMM2902) completed the first patient in (FPI).
View more
2022-06-15
ImmuneOnco’s IMM27M,an ADCC-enhanced CTLA-4 antibody completed the first patient enrollment and dosing
On June 15, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (hereinafter referred to as "ImmuneOnco") announced that our newly developed ADCC-enhanced CTLA-4 antibody (IMM27M) completed the first patient enrollment and first dosing. The administration and the infusion process was smooth.
View more
2022-05-17
The Phase Ib/II clinical study of IMM01 combined with PD-1 antibody in the treatment of relapsed and refractory malignant tumors completed the first patient enrollment and administration
On May 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the FPI in the Phase Ib/II clinical study of first domestic SIRPα-Fc fusion protein targeting human CD47 (project number: IMM01) combined with PD-1 antibody for relapsed and refractory malignant tumors (clinical research project number: IMM01-04). The first subject was enrolled and dosed successfully.
View more
2022-04-01
ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trials
On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Frank Xiaodong Gan was appointed as the senior vice president of our Company in April 2022, and is responsible for clinical development of our Group in the United States.
View more
总计 53 123456789